Keytruda® (pembrolizumab) as perioperative treatment with standard of care (soc) adjuvant therapy significantly improved event-free survival compared to soc alone in patients with resectable locally advanced head and neck squamous cell carcinoma

Rahway, n.j.--(business wire)---- $mrk #mrk--merck (nyse: mrk), known as msd outside of the united states and canada, today announced results from the phase 3 keynote-689 trial evaluating keytruda® (pembrolizumab), merck's anti-pd-1 therapy, as a perioperative treatment regimen for patients with stage iii or iva, resected, locally advanced head and neck squamous cell carcinoma (la-hnscc). results at the first interim analysis of the trial showed keytruda significantly improved event-free survival (efs) as pa.
SOC Ratings Summary
SOC Quant Ranking